ClinicalTrials.gg
RecruitingNCT07253181TREASUREUpdated Aug 19, 2026

Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours

A Phase 3 interventional study of Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg) in Acute Ischemic Stroke, Large Vessel Occlusion and Transportation of Patients, sponsored by Xuanwu Hospital, Beijing. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Xuanwu Hospital, Beijing · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
572
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing tenecteplase in Ischemic Stroke — 32 open to participants now, 32 under way, 25 of them phase 3. Tenecteplase · Ischemic Stroke.

Planned enrollment
24th of 59
572 · median 466
Started
2026
with 10 others
Phase 3
37 of 59
23 open now
Primary completion
2028-03
later than 17 of 31 live
Registered
48th of 59
by date
Lead sponsor
4 of 59
Xuanwu Hospital, Beijing

Among the 59 studies testing tenecteplase in Ischemic Stroke, this one is the 24th largest by planned enrollment, is one of 11 that started in 2026, is one of 37 in phase 3, reaches primary completion later than 17 of the 31 other live ones, and was the 48th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

32 of the 59 studies testing tenecteplase in Ischemic Stroke are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About tenecteplase

Tenecteplase: first FDA approval 2000 (TNKASE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing tenecteplase in Ischemic Stroke, or all of them as a file.
02

Study summary

This study will address the efficacy and safety of Tenecteplase administered in non-endovascular capable center (nECC) in patients with acute ischemic stroke (AIS) caused by anterior circulation large vessel occlusion (acLVO) who present in the 4.5- to 24-hour time window before interhospital transfer to an endovascular capable center (ECC) for endovascular treatment (EVT).

  • Primary objective: To evaluate the efficacy and safety of Tenecteplase administration at a nECC before EVT transfer compared with standard of care
  • Secondary objective: To evaluate the impact of time from needle-to-arterial puncture on clinical outcomes Patients who meet inclusion criteria will be randomized to Tenecteplase (0.25mg/kg, maximum 25mg) before transfer or standard of care. A single bolus dose should be injected over 5 seconds.
03

Conditions studied

  • Acute Ischemic Stroke
  • Large Vessel Occlusion
  • Transportation of Patients

Browse trials for

Keywords

  • interhospital transfer
  • acute ischemic stroke
  • anterior circulation large vessel occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 18 years or older;
  • AIS symptom onset to treatment initiation within 4.5 to 24 hours, stroke onset is defined as the time the patient was last known to be well (including wake-up stroke and unwitnessed stroke);
  • Signs and symptoms consistent with the diagnosis of an acute anterior circulation ischemic stroke involving occlusion of the internal carotid artery (ICA), M1 or proximal M2 vessels;
  • Functionally independent (mRS 0-2) prior to stroke onset;
  • Baseline National Institute of Health Stroke Scale (NIHSS) of 6-25;
  • Intended to transfer to ECCs for EVT (patient transfer), or intended to transfer a neurointerventionalist from the ECC for EVT (physician transfer);
  • Written from patients or legally authorized representatives;
  • Neuroimaging: large vessel occlusion (ICA, M1, proximal M2) by MRA or CTA AND the target mismatch profile on computed tomography perfusion (CTP) or magnetic resonance perfusion (MRP), defined as an ischemic core volume \<70mL, mismatch volume ≥15mL and mismatch ratio ≥1.8;

Alternative neuroimaging (if CTP or MRP is technically inadequate or unavailable):

An Alberta Stroke Program Early CT Score (ASPECTS) score ≥7 on NCCT or MRI scan;

Exclusion criteria

Exclusion Criteria:

  • Known or allergy to any ingredients of Tenecteplase;
  • Intended to receive IVT as standard-of-care therapy;
  • Rapidly improving symptoms with NIHSS score \<6 before randomization;
  • Any for IVT except for the time criterion;
  • Known hereditary or acquired hemorrhagic diathesis;
  • Impairment in coagulation due to comorbid disease or anticoagulant use. If on warfarin, >1.7 or prothrombin time >15s; if use of any direct oral anticoagulant within the last 48 hours; if on any full dose heparin/heparinoid within the last 24 hours;
  • Ischemic stroke or myocardial infarction in previous 3 months
  • Previous intracranial hemorrhage, active internal bleeding (gastrointestinal or urinary tract hemorrhage) in previous 3 months;
  • Severe, uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg);
  • Other serious, advanced or terminal illness with less than 6 months;
  • Baseline blood glucose \<50mg/dl or >400mg/dl;
  • Contraindication to imaging with contrast agents;
  • Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA or MRA (e.g. bilateral MCA occlusions, or an MCA and a basilar artery occlusion);
  • Extensive early ischemic change on non-contrast CT or MRI-DWI estimated to be >1/3 MCA territory, or significant hypodensity outside the Tmax>6s perfusion lesion that invalidates mismatch criteria (if patient is enrolled based on CT perfusion criteria); any CT or MRI findings indicative of a high risk of sICH related to potential intravenous tenecteplase treatment in the judgement of the investigator;
  • Evidence of intracranial tumor (mass effect), acute intracranial hemorrhage, or arteriovenous malformation;
  • Current participation in another drug or device study;
  • Suspected endocarditis;
  • Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
572 participants (estimated)

Study arms

  • Experimental
    Tenecteplase before transfer

    Patients will receive intravenous Tenecteplase 0.25 mg/kg body-weight up to a maximum of 25mg. Tenecteplase is for IV administration only. A single bolus dose should be administered over 5 seconds based on patient weight. Transport to ECCs or transfer physician for EVT should be initiated as early as possible after administration according to Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023.

    Drug: Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)

  • No intervention
    Standard of care

    Patients will receive standard treatment and be directly transferred to ECCs or transfer physician for EVT according to Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023.

Interventions

06

What researchers measure

Primary outcomes

  1. Level of disability (ordinal mRS score)

    the ordinal score on the modified Rankin scale; The modified Rankin scale is a measure of disability, with scores ranging from 0 (no symptoms) to 6 (death).

    Time frame: at 90 (±7) days

Secondary outcomes

  1. Excellent outcome

    mRS of 0-1 vs. 2-6

    Time frame: at 90 (±7) days

  2. Functional independence

    mRS of 0-2 vs. 3-6

    Time frame: at 90 (±7) days

  3. Ambulatory and self-care capable

    mRS of 0-3 vs. 4-6

    Time frame: at 90 (±7) days

  4. Health-related quality of life

    Score on the EuroQol Group 5-Dimension 5-Level \[EQ-5D-5L\] questionnaire; range, -0.39 to 1, with higher scores indicating better quality of life)

    Time frame: at 90 (±7) days

  5. Incidence of arterial recanalization

    Arterial imaging performed at ECC arrival, either CTA/MRA/or first run of DSA

    Time frame: Day 1

  6. First pass reperfusion

    First pass reperfusion refers to achievement of recanalization by single pass, near-complete to complete recanalization of the occlusion site (eTICI 2c or 3) and no need for rescue treatment

    Time frame: intraoperative, immediately after the first pass

  7. Successful reperfusion

    successful reperfusion is defined as extended Treatment In Cerebral Ischemia (eTICI) grades of 2b, 2c or 3

    Time frame: immediately after the endovascular intervention

  8. Recanalization

    Time frame: at 24 (±12) hours

Other outcomes

  1. Symptomatic intracranial hemorrhage (sICH)

    using Heidelberg criteria

    Time frame: within 36 hours

  2. Parenchymal hematoma type 2 (PH2)

    Time frame: within 36 hours

  3. All-cause mortality

    Time frame: up to 90 (±7) days

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — According to Chinese laws and regulations, the IPD will not be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2028, 26 months after the start.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 26 months is below that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 28, 2025
StartActual
Jan 6, 2026
Primary completionEst.
Mar 30, 2028
CompletionEst.
Mar 30, 2028
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07253181
Collaborators
Boehringer Ingelheim (China) Investment Co., Ltd, Jeffrey Saver, Maarten Lansberg, Thanh N. Nguyen, Pierre Seners, Jens Fiehler, Raul G. Nogueira
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Jan 6, 2026
Primary completion
Mar 30, 2028 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Aug 19, 2026

Study contacts

Gaoting Ma, MD
Contact
demo_doctor@163.com
+8683198082
Junwei Hao, MD, PhD
principal investigator · Xuanwu Hospital, Beijing

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion